News

Medical Developments International (MVP) is delighted to advise it has entered into an exclusive agreement with PSUK to supply its range of respiratory devices in the UK. The agreement includes minimum quantities for the next 3 years that will drive ongoing sales growth of MVP respiratory devices in the UK. PSUK?s parent company, Phoenix Healthcare […]

Medical Developments International (MVP) is delighted to advise it has entered into an exclusive agreement with PSUK to supply its range of respiratory devices in the UK. The agreement includes minimum quantities for the next 3 years that will drive ongoing sales growth of MVP respiratory devices in the UK. PSUK’s parent company, Phoenix Healthcare […]

SINGAPORE: A year-long trial is being conducted on two medications to ensure patients get a faster and more effective delivery of pain relief. The Singapore General Hospital (SGH) and Singapore Civil Defence Force (SCDF) will study the suitability of Penthrox and Tramadol for early pain relief. Penthrox is delivered through an inhaler while Tramadol is […]

Medical Developments International Limited (ASX:MVP) has received approval from the Medicines Control Council (MCC) in South Africa to market and sell its inhaled analgesic product, ?Penthrox?? for pain relief from trauma and surgical procedures. The approval gives MVP?s partner in South Africa, LINK Healthcare Pte Ltd (through its wholly owned subsidiary Equity Pharmaceuticals Pty Ltd), […]

Update on European Marketing Application In November 2013, Medical Developments International (MVP) submitted its regulatory dossier and Marketing Authorisation Application for review to ?The Medicines and Healthcare Products Regulatory Agency? (?MHRA?) in England. On 27 January, 2014 MVP received its first round of questions from the MHRA. We have completed our responses and we are […]

?THOROUGH QT/QTc? PENTHROX? CLINICAL TRIAL SUCCESSFULLY MEETS ALL PRIMARY AND SECONDARY OBJECTIVES

Medical Developments International Limited (ASX:MVP) is delighted to announce it has completed the
Thorough QT/QTc Clinical Trial.

In August 2012 MVP announced it had entered into a research and development program with the CSIRO designed to introduce a new, more efficient, significantly lower manufacturing cost process for the pharmaceutical compound used in Penthrox?. We are delighted to announce the first milestone, which is to manufacture commercial grade methoxyflurane in much larger quantities […]

Download CEO’s & Chairman’s Report as PDF RECORD PROFIT STRONG GROWTH AND 3 CENTS FULLY FRANKED INTERIM DIVIDEND Medical Developments International Ltd. (ASX:MVP) delivered a Record Net Profit After Tax of $1,444,000 for the half year ended 31 December 2012, which represents a 25% increase on H1FY2012 ($1,156,000). The financial result represents: 23% increase in […]

20 January 2013 ASX ANOUNCEMENT RESULTS OF PIVOTAL PHASE III CLINICAL TRIAL Methoxyflurane inhalation demonstrated to be highly effective analgesic. Methoxyflurane provided clinically-significant pain reduction. Demonstrated safety of methoxyflurane for the treatment of acute pain. Primary Endpoint and Objective of the study was met. All Secondary Endpoints and Objectives were met. MVP Comment Medical Developments […]

27 December 2012 ASX ANNOUNCEMENT Significant Developments and Opportunities in Asthma Devices Consistent with MVP?s strategy of broadening the availability and use of its core products, MVP makes the following? announcement about positive developments in its asthma range of products. UPDATE ON AUSTRALIA On 31 October MVP announced the winning of a competitive tender and […]